Pending Clinical Trials
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Phase: |
Phase II - Phase 2 |
Trial for Patients with: |
Dedifferentiated Liposarcoma who have had at least one prior chemotherapy regimen for dedifferentiated liposarcoma |
Treatment involved: |
IPI 504 (Retaspimycin) |
Age Requirement: |
18 and older |
Location: |
Dana Farber in Boston, Massachusetts |
| Description | The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma. |
| Specific Conditions: | |
| Trial Start Date: | December 2009 |
| Trial End Date: | December 2010 (estimated) |
| ClinicalTrials.gov: | NCT00969917: detailed information at ClinicalTrials.gov |
| Full Title: | A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma |
| This page was last updated on: | September 2, 2009 |